<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To investigate the impact of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> (MetSD) on the development of intracranial atherosclerotic <z:hpo ids='HP_0001297'>stroke</z:hpo>, the authors evaluated the components of the MetSD in 512 patients with <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The MetSD was observed most frequently in patients with intracranial <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> (p = 0.007) </plain></SENT>
<SENT sid="2" pm="."><plain>In multiple regression analysis, the MetSD, but not conventional risk factors, was independently associated with intracranial <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> (p = 0.005) </plain></SENT>
<SENT sid="3" pm="."><plain>The results suggest that treatment of <z:mp ids='MP_0005266'>metabolic abnormalities</z:mp> may be an important prevention strategy for intracranial <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
</text></document>